30 August 2024: ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following corporate update in regards the Company’s ongoing administration process (“Administration Process”) and notifies of the cancellation of the Company’s ordinary shares (“Ordinary Shares”) from trading on AIM.